

# Douglas T Fearon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7473897/publications.pdf>

Version: 2024-02-01

94  
papers

19,877  
citations

30047

54  
h-index

40954

93  
g-index

99  
all docs

99  
docs citations

99  
times ranked

24302  
citing authors

#	ARTICLE	IF	CITATIONS
1	Carcinomas assemble a filamentous CXCL12â€“keratin-19 coating that suppresses T cellâ€“mediated immune attack. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	32
2	AMD3100/Plerixafor overcomes immune inhibition by the CXCL12â€“KRT19 coating on pancreatic and colorectal cancer cells. British Journal of Cancer, 2021, 125, 149-151.	2.9	11
3	CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28960-28970.	3.3	150
4	Cancer cell CCR2 orchestrates suppression of the adaptive immune response. Journal of Experimental Medicine, 2020, 217, .	4.2	32
5	A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews Cancer, 2020, 20, 174-186.	12.8	2,012
6	Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature, 2020, 581, 100-105.	13.7	628
7	Embryonic FAP+ lymphoid tissue organizer cells generate the reticular network of adult lymph nodes. Journal of Experimental Medicine, 2019, 216, 2242-2252.	4.2	44
8	Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13490-13497.	3.3	115
9	Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature, 2019, 570, 246-251.	13.7	550
10	Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E743-E752.	3.3	89
11	Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science, 2018, 361, .	6.0	893
12	Stromal Cells in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2018, 1060, 99-114.	0.8	208
13	Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science, 2018, 360, .	6.0	177
14	Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. Journal of Experimental Medicine, 2017, 214, 579-596.	4.2	1,582
15	Connecting the Metabolic and Immune Responses to Cancer. Trends in Molecular Medicine, 2017, 23, 451-464.	3.5	55
16	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 2017, 551, 512-516.	13.7	854
17	Immune-Suppressing Cellular Elements of the Tumor Microenvironment. Annual Review of Cancer Biology, 2017, 1, 241-255.	2.3	25
18	Combination immunotherapy for cancer. Journal of Experimental Medicine, 2016, 213, 1115-1115.	4.2	4

#	ARTICLE	IF	CITATIONS
19	Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 219-226.	2.0	6
20	De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunology Research, 2016, 4, 279-288.	1.6	29
21	Disruption of Anti-tumor T Cell Responses by Cancer-Associated Fibroblasts. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 77-98.	0.1	1
22	Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell Metabolism, 2016, 24, 672-684.	7.2	264
23	T cell exclusion, immune privilege, and the tumor microenvironment. Science, 2015, 348, 74-80.	6.0	1,735
24	Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics. Cancer Research, 2015, 75, 296-305.	0.4	283
25	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
26	Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-1 and Heme Oxygenase-1. Cancer Immunology Research, 2014, 2, 121-126.	1.6	127
27	Fibroblastic reticular cells of the lymph node are required for retention of resting but not activated CD8 <sup>+</sup> T cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12139-12144.	3.3	115
28	The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance. Cancer Immunology Research, 2014, 2, 187-193.	1.6	223
29	Transcriptional regulation of effector and memory CD8 <sup>+</sup> T cell fates. Current Opinion in Immunology, 2013, 25, 321-328.	2.4	27
30	Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20212-20217.	3.3	1,482
31	Tumour immunology. Current Opinion in Immunology, 2013, 25, 189-191.	2.4	5
32	Depletion of stromal cells expressing fibroblast activation protein-1 from skeletal muscle and bone marrow results in cachexia and anemia. Journal of Experimental Medicine, 2013, 210, 1137-1151.	4.2	304
33	Control of HIV infection: Escape from the shadow of Blimp-1. European Journal of Immunology, 2013, 43, 323-326.	1.6	8
34	Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8 <sup>+</sup> T cell. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2223-9.	3.3	70
35	Maintenance of T Cell Function in the Face of Chronic Antigen Stimulation and Repeated Reactivation for a Latent Virus Infection. Journal of Immunology, 2012, 188, 2173-2178.	0.4	60
36	siRNA high-throughput kinase library screen identifies protein kinase, DNA-activated catalytic polypeptide to play a role in MyD88-induced IFN $\alpha$ 2 activation and IL-6 secretion. Biotechnology and Applied Biochemistry, 2012, 59, 6-14.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Tâ€betâ€mediated differentiation of the activated CD8<sup>+</sup> T cell. European Journal of Immunology, 2011, 41, 60-66.	1.6	31
38	Cutting Edge: Virus-Specific CD8+ T Cell Clones and the Maintenance of Replicative Function during a Persistent Viral Infection. Journal of Immunology, 2010, 185, 7141-7145.	0.4	10
39	Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Proteinâ€±. Science, 2010, 330, 827-830.	6.0	952
40	Pillars Article: CD19: Lowering the threshold for antigen receptor stimulation of B lymphocytes. Science, 1992. 256: 105-107. Journal of Immunology, 2010, 184, 2233-5.	0.4	2
41	Secondary Replicative Function of CD8 <sup>+</sup> T Cells That Had Developed an Effector Phenotype. Science, 2009, 323, 505-509.	6.0	145
42	Pathways of memory CD8<sup>+</sup> Tâ€cell development. European Journal of Immunology, 2009, 39, 2083-2087.	1.6	48
43	The precursors of memory: models and controversies. Nature Reviews Immunology, 2009, 9, 662-668.	10.6	170
44	Inflammation and Cardiovascular Disease. Circulation, 2008, 117, 2577-2579.	1.6	143
45	The Expansion and Maintenance of Antigenâ€selected CD8+ T Cell Clones. Advances in Immunology, 2007, 96, 103-139.	1.1	29
46	Loss of T cell receptor-induced Bmi-1 in the KLRG1<sup>+</sup>senescent CD8<sup>+</sup>T lymphocyte. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13414-13419.	3.3	80
47	The rationale for the Ilâ€2â€independent generation of the selfâ€renewing central memory CD8 + T cells. Immunological Reviews, 2006, 211, 104-118.	2.8	26
48	Identifying genes important for spermatogonial stem cell self-renewal and survival. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9524-9529.	3.3	377
49	CD27 mediates interleukin-2-independent clonal expansion of the CD8+ T cell without effector differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19454-19459.	3.3	57
50	BCL6b mediates the enhanced magnitude of the secondary response of memory CD8+ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7418-7425.	3.3	76
51	The proto-oncogene BCL-6 is expressed in olfactory sensory neurons. Neuroscience Research, 2005, 53, 189-200.	1.0	11
52	IgM and stromal cell-associated heparan sulfate / heparin as complement-independent ligands for CD19. European Journal of Immunology, 2001, 31, 2189-2199.	1.6	32
53	From Innate Immunity to Regulation of B Cell Differentiation in the Germinal Centre. Biochemical Society Transactions, 2000, 28, A487-A487.	1.6	0
54	Enhanced immunogenicity of aldehyde-bearing antigens: a possible link between innate and adaptive immunity. European Journal of Immunology, 2000, 30, 2881-2887.	1.6	69

#	ARTICLE	IF	CITATIONS
55	Innate immunityâ€™s beginning to fulfill its promise?. <i>Nature Immunology</i> , 2000, 1, 102-103.	7.0	24
56	Suppression of Signal Transducer and Activator of Transcription 3â€™-Dependent B Lymphocyte Terminal Differentiation by Bcl-6. <i>Journal of Experimental Medicine</i> , 2000, 192, 1841-1848.	4.2	206
57	Regulation of B Lymphocyte Responses to Foreign and Self-Antigens by the CD19/CD21 Complex. <i>Annual Review of Immunology</i> , 2000, 18, 393-422.	9.5	480
58	CD19 as a Membrane-Anchored Adaptor Protein of B Lymphocytes: Costimulation of Lipid and Protein Kinases by Recruitment of Vav. <i>Immunity</i> , 1998, 8, 635-645.	6.6	177
59	The complement system and adaptive immunity. <i>Seminars in Immunology</i> , 1998, 10, 355-361.	2.7	95
60	Inhibition of the B Cell by CD22: A Requirement for Lyn. <i>Journal of Experimental Medicine</i> , 1998, 187, 807-811.	4.2	245
61	Seeking wisdom in innate immunity. <i>Nature</i> , 1997, 388, 323-324.	13.7	233
62	Counterregulation by the Coreceptors CD19 and CD22 of MAP Kinase Activation by Membrane Immunoglobulin. <i>Immunity</i> , 1997, 7, 59-67.	6.6	115
63	Downregulated Expression of SHP-1 in Burkitt Lymphomas and Germinal Center B Lymphocytes. <i>Journal of Experimental Medicine</i> , 1997, 186, 1575-1583.	4.2	71
64	The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera. <i>Oncogene</i> , 1997, 14, 1215-1222.	2.6	49
65	Happy coupling: Recruiting both antigen and effector function. <i>Nature Biotechnology</i> , 1997, 15, 618-619.	9.4	5
66	Co-receptors of B lymphocytes. <i>Current Opinion in Immunology</i> , 1997, 9, 324-329.	2.4	75
67	Innate immunity Innate pathways that control acquired immunity. <i>Current Opinion in Immunology</i> , 1997, 9, 1-3.	2.4	87
68	Self-renewal of B-1 lymphocytes is dependent on CD19. <i>European Journal of Immunology</i> , 1996, 26, 238-242.	1.6	115
69	Activation of B lymphocytes: integrating signals from CD19, CD22 and FcÎ³RIIb1. <i>Current Opinion in Immunology</i> , 1996, 8, 378-382.	2.4	64
70	Therapeutic uses of recombinant complement protein inhibitors. <i>Seminars in Immunopathology</i> , 1994, 15, 417-431.	4.0	53
71	Innate immunity: 50 ways to kill a microbe. <i>Current Opinion in Immunology</i> , 1994, 6, 73-74.	2.4	16
72	The CD19-CR2-TAPA-1 complex, CD45 and signaling by the antigen receptor of B lymphocytes. <i>Current Opinion in Immunology</i> , 1993, 5, 341-348.	2.4	74

#	ARTICLE	IF	CITATIONS
73	Structure and Function of the Complement Receptors, CR1 (CD35) and CR2 (CD21). <i>Advances in Immunology</i> , 1989, 46, 183-219.	1.1	404
74	Human receptor for C3b/C4b: Complement receptor type I. <i>Methods in Enzymology</i> , 1987, 150, 579-585.	0.4	4
75	Epstein-barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. <i>Cell</i> , 1987, 50, 203-213.	13.5	481
76	CR1 and the cell membrane proteins that bind C3 and C4. <i>Immunologic Research</i> , 1987, 6, 192-209.	1.3	23
77	Purification of the B lymphocyte receptor for the C3d fragment of complement and the Epstein-Barr virus by monoclonal antibody affinity chromatography, and assessment of its functional capacities. <i>Journal of Immunological Methods</i> , 1986, 92, 79-87.	0.6	16
78	Decreased Expression of C3b Receptor (CR1) on Erythrocytes of Patients with Systemic Lupus erythematosus Contrasts with Its Normal Expression in Other Systemic Diseases and Does Not Correlate with the Occurrence or Severity of SLE Nephritis. <i>Complement (Basel, Switzerland)</i> , 1986, 3, 88-96.	1.0	12
79	The role of receptors for complement in the induction of polyclonal B-cell proliferation and differentiation. <i>Journal of Clinical Immunology</i> , 1986, 6, 65-73.	2.0	32
80	Neutrophil Activation in Thermal Injury as Assessed by Increased Expression of Complement Receptors. <i>New England Journal of Medicine</i> , 1986, 314, 948-953.	13.9	151
81	Rapid purification of the human C3b/C4b receptor (CR1) by monoclonal antibody affinity chromatography. <i>Journal of Immunological Methods</i> , 1985, 82, 303-313.	0.6	31
82	Biocompatibility of dialysis membranes: Effects of chronic complement activation. <i>Kidney International</i> , 1984, 26, 194-200.	2.6	229
83	The role of antibody in the activation of the alternative complement pathway. <i>Seminars in Immunopathology</i> , 1983, 6, 361-371.	4.0	92
84	Mode of Inheritance of Decreased C3b Receptors on Erythrocytes of Patients with Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 1982, 307, 981-986.	13.9	334
85	Structural Determinants of the Capacity of Heparin to Inhibit the Formation of the Human Amplification C3 Convertase. <i>Journal of Clinical Investigation</i> , 1981, 67, 223-228.	3.9	148
86	The Alternative Pathway of Complement â€” A System for Host Resistance to Microbial Infection. <i>New England Journal of Medicine</i> , 1980, 303, 259-263.	13.9	181
87	Clinical and biochemical effects of impeded androgen (oxymetholone) therapy of hereditary angioedema. <i>Journal of Allergy and Clinical Immunology</i> , 1979, 64, 275-280.	1.5	31
88	Tranexamic acid: Preoperative prophylactic therapy for patients with hereditary angioneurotic edema. <i>Journal of Allergy and Clinical Immunology</i> , 1977, 60, 38-40.	1.5	46
89	Glomerulonephritis, Complement and C3NeF. <i>New England Journal of Medicine</i> , 1976, 294, 495-497.	13.9	5
90	INHIBITION OF COMPLEMENT-DERIVED ENZYMES. <i>Annals of the New York Academy of Sciences</i> , 1975, 256, 441-450.	1.8	12

#	ARTICLE	IF	CITATIONS
91	Activation of the Properdin Pathway of Complement in Patients with Gram-Negative Bacteremia. New England Journal of Medicine, 1975, 292, 937-940.	13.9	247
92	PROPERDIN FACTOR D. Journal of Experimental Medicine, 1974, 140, 426-436.	4.2	52
93	PROPERDIN FACTOR D: CHARACTERIZATION OF ITS ACTIVE SITE AND ISOLATION OF THE PRECURSOR FORM. Journal of Experimental Medicine, 1974, 139, 355-366.	4.2	124
94	FORMATION OF A HEMOLYTICALLY ACTIVE CELLULAR INTERMEDIATE BY THE INTERACTION BETWEEN PROPERDIN FACTORS B AND D AND THE ACTIVATED THIRD COMPONENT OF COMPLEMENT. Journal of Experimental Medicine, 1973, 138, 1305-1313.	4.2	178